U.S. Markets closed
  • S&P 500

    4,357.73
    -75.26 (-1.70%)
     
  • Dow 30

    33,970.47
    -614.41 (-1.78%)
     
  • Nasdaq

    14,713.90
    -330.06 (-2.19%)
     
  • Russell 2000

    2,182.20
    -54.67 (-2.44%)
     
  • Crude Oil

    70.48
    -1.49 (-2.07%)
     
  • Gold

    1,764.70
    +13.30 (+0.76%)
     
  • Silver

    22.22
    -0.08 (-0.36%)
     
  • EUR/USD

    1.1729
    -0.0003 (-0.0235%)
     
  • 10-Yr Bond

    1.3090
    -0.0610 (-4.45%)
     
  • Vix

    25.71
    +4.90 (+23.55%)
     
  • GBP/USD

    1.3663
    -0.0075 (-0.5438%)
     
  • USD/JPY

    109.3810
    -0.5140 (-0.4677%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,076.57
    -57.81 (-5.10%)
     
  • FTSE 100

    6,903.91
    -59.73 (-0.86%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Compugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor Studies

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Compugen Ltd (NASDAQ: CGENreports updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and a dose-escalation combination study with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab).

  • COM701 is an antibody targeting PVRIG, a novel immune checkpoint.

  • Data highlight as of the data cutoff of December 14, 2020:

  • COM701 and Opdivo combination arm showed a disease control rate of 66.7% with best responses of the complete response of 6.7%, the partial response of 6.7%, and stable disease rate of 53.3%.

  • Durable responses of confirmed stable disease of six months or more were observed in three patients.

  • In the COM701 monotherapy arm, the patient with primary peritoneal cancer with durable confirmed partial response remains on study treatment at 62 weeks.

  • The patient with pancreatic cancer, refractory to all three prior lines of the standard of care therapy with the durable confirmed stable disease, was on study treatment for 31 weeks.

  • Six of the 20 patients enrolled in the monotherapy expansion cohort had the best responses of stable disease. No new safety findings were observed.

  • Additional clinical data and initial correlative assessments of biological samples will be presented at the American Society of Clinical Oncology 2021 annual meeting.

  • Price Action: CGEN increased 11% at $11.5 in premarket trading on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.